According to the results of the REACH-2 trial, ramucirumab has also been approved as a second-line treatment for HCC in patients who have progressed to or are intolerant to sorafenib with alpha-fetoprotein (AFP) ≥ 400 ng/mL [8]. The gene discussed is AFP; the disease is hepatocellular carcinoma.